Ariad suspends sales of blood cancer drug Iclusig

(Reuters) - Ariad Pharmaceuticals Inc said it was suspending the sale of its blood cancer drug, Iclusig, barely two weeks after it stopped a late-stage trial of the drug due to safety concerns. The decision was taken in response to a request by the U.S. Food and Drug Administration on Wednesday afternoon, Ariad said in a statement. (Reporting by Esha Dey in Bangalore; Editing by Sriraj Kalluvila)



via Health News Headlines - Yahoo! News http://news.yahoo.com/ariad-suspends-sales-blood-cancer-drug-iclusig-114127397--finance.html